Erasca (ERAS) has had the highest return since January 1, 2026 by a mid-cap US stock, returning 412.4%.
| ASSET | % RETURN |
|---|---|
Erasca (ERAS) | 412.4% |
AXT (AXTI) | 380% |
Aehr Test Systems (AEHR) | 298.95% |
Immunitybio (IBRX) | 281.19% |
Xanadu Quantum Technologies Limited Class B Subordinate Voting Shares (XNDU) | 253.22% |
Ichor (ICHR) | 242.63% |
Enliven Therapeutics (ELVN) | 210.39% |
Ultra Clean (UCTT) | 204.17% |
Tango Therapeutics (TNGX) | 201.02% |
Babcock & Wilcox Enterprises (BW) | 182.46% |
Almonty Industries Inc Common Shares (ALM) | 166.74% |
Alumis (ALMS) | 155.78% |
Viavi Solutions (VIAV) | 144.52% |
Iridium Communications (IRDM) | 140.32% |
Fastly, Inc Class A Common Stock (FSLY) | 137.75% |
Day One Biopharmaceuticals (DAWN) | 131.11% |
Oruka Therapeutics (ORKA) | 127.38% |
Dianthus Therapeutics (DNTH) | 126.85% |
Veradermics (MANE) | 124.38% |
Powell Industries (POWL) | 123.26% |
Spyre Therapeutics (SYRE) | 122.86% |
Amprius Technologies (AMPX) | 120.95% |
CommScope (VISN) | 119.52% |
Aura Minerals Inc Common Shares (AUGO) | 115.11% |
Relay Therapeutics (RLAY) | 100.72% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
